Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Ratios

Bicycle Therapeutics (BCYC) EPS (Basic) (2018 - 2026)

Bicycle Therapeutics (BCYC) has disclosed EPS (Basic) for 9 consecutive years, with -$0.87 as the latest value for Q1 2026.

  • For Q1 2026, EPS (Basic) rose 1.14% year-over-year to -$0.87; the TTM value through Mar 2026 reached -$3.15, changed 0.32%, while the annual FY2025 figure was -$3.16, 8.97% down from the prior year.
  • EPS (Basic) hit -$0.87 in Q1 2026 for Bicycle Therapeutics, down from -$0.29 in the prior quarter.
  • Across five years, EPS (Basic) topped out at -$0.29 in Q4 2025 and bottomed at -$1.41 in Q2 2023.
  • Average EPS (Basic) over 5 years is -$0.93, with a median of -$0.9 recorded in 2022.
  • Year-over-year, EPS (Basic) crashed 65.57% in 2022 and then surged 61.33% in 2025.
  • Bicycle Therapeutics' EPS (Basic) stood at -$1.01 in 2022, then decreased by 11.88% to -$1.13 in 2023, then skyrocketed by 33.63% to -$0.75 in 2024, then soared by 61.33% to -$0.29 in 2025, then plummeted by 200.0% to -$0.87 in 2026.
  • According to Business Quant data, EPS (Basic) over the past three periods came in at -$0.87, -$0.29, and -$0.85 for Q1 2026, Q4 2025, and Q3 2025 respectively.